Articles Related to chemotherapy

Desirable treatment options for inoperable esophageal cancer considering not only overall survival (OS) but also quality of life (QOL) during the entire clinical course remain unclear. We evaluated OS and QOL during the clinical course of patients with inoperable esophageal cancer undergoing chemoradiation or radiation. Forty-four patients with inoperable esophageal cancer between 2015 and 2020 were included in this retrospective study.

View complete article: PDF  |  Full-text

Glioblastoma is the most common and most deadly type of primary brain malignant tumors. despite applying the best trimodal treatment consisting of surgery chemoterapy and radiotherapy, there are few patients who survive decades after treatment.

View complete article: PDF  |  Full-text

Temozolomide is an orally administered chemotherapeutic drug used concurrently with radiation for the treatment of newly diagnosed glioblastoma. Although the addition of Temozolomide has shown to improve overall survival, it is commonly associated with haematological complications. Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that is also used off-label for temozolomide-induced aplastic anaemia.

View complete article: PDF  |  Full-text

The aim of this study was to assess the potential acute adverse effects associated with the use of anti-glaucoma medications among glaucoma patients with Glucose-6-Phosphate Dehydrogenase deficiency.

View complete article: PDF  |  Full-text

To evaluate the quality of life and the impairment of the emotional function of women with breast cancer under chemotherapeutic treatment, in relation to sociodemographic and clinical characteristics. Observational, longitudinal, and analytical research; conducted between 2013 to 2015 with 67 women in three stages of chemotherapy treatment in a public referral teaching hospital in Paraná. Two questionnaires, one for socio-demographic and clinical data, and the Quality of Life Questionnaire-C30 were used for data collection.

View complete article: PDF  |  Full-text

Breast cancer is caused by genetic abnormalities resulting in uncontrolled growth of breast cells, and is the most commonly diagnosed cancer amongst women. The clinical use of liposomal-based drugs to treat solid tumors such as breast cancer has been shown to improve the overall pharmacological properties of otherwise “unencapsulated” cytotoxic agents.

View complete article: PDF  |  Full-text

Gemcitabine is a pyrimidine analog and cisplatin is a platinum agent, they are usually combined to form a chemotherapeutic doublet used to treat different types of oncological cancers, including non-small cell lung cancer (NSCLC). Although these agents are not known to cause such events, few cases related to possible cardiotoxicity side effects have been reported ; including angina, chronic heart failure, arrhythmias, and cardiac ischemia. A 52-year-old African male presented with Stage IV lung adenocarcinoma metastatic to the bone, pleura and lymph node, EGFR wild type. Patient has a history of hypertension, diabetes, and atrial fibrillation and on rate control medications. He was treated initially with cisplatin-gemcitabine, after which he developed cardiomyopathy.

View complete article: PDF  |  Full-text

This study tested for the effects of generic liposome-encapsulated doxorubicin hydrochloride (generic doxorubicin) compared to reference-pegylated liposomal doxorubicin hydrochloride (reference doxorubicin) as a treatment for patients afflicted with epithelial ovarian carcinoma whose disease has progressed after platinum-based chemotherapy. Chart-reviews of actual patients enrolled in a community-based NIH trial suggest that both generic and reference liposomal doxorubicin hydrochloride (HCl) are equally effective as treatment for ovarian cancer carcinoma.

View complete article: PDF  |  Full-text

Objective: Concomitant chemoradiation (RCT) represents the standard of care for locally-advanced nasopharyngeal carcinoma (NPC).Nevertheless induction chemotherapy (IC) followed by RCT is currently an attractive approach. Some trials showed a survival benefit of this therapeutic strategy. The aim of this study was to analyze complete clinical response (CCR) after IC and to assess its impact on disease control and survival.

View complete article: PDF  |  Full-text

Objective: To evaluate the compliance of chemotherapy administration duration by comparing the peripheral venous catheter (PVC) route with the implantable venous access device (IVAD).Keywords: Chemotherapy; Gravity perfusion; Peripheral venous; Implantable venous access deviceIntroduction Methods: This was a retrospective study that analyzed 566 cycles of chemotherapy administered by PVC at the Cancer Unit of Yalgado Ouédraogo University Hospital and 258 cycles administered by IVAD at the Oncology Department of Treichville University Hospital in Abidjan. We compared the differences between the programmed duration of chemotherapy and the actual duration of administration according to the two routes of administration.

View complete article: PDF  |  Full-text

Sarcomas of the head and neck are very rare accounting for approximately 1% of all head and neck neoplasms. Primary osteosarcomas of the nasal cavity are less than 0.5% of the osteosarcomas occur in this location. Because of the rarity of this presentation, we report a case of a 54 year old male with primary osteosarcoma arising de novo from the nasal cavity, presented with left epistaxis and bilateral nasal obstruction.

View complete article: PDF  |  Full-text

Investigate the use of cardiac resynchronization therapy (CRT) in cancer patients with heart failure (HF); assess factors associated with ischemic and non-ischemic HF. Many newer cancer therapies are cardiotoxic; thus, the incidence of HF has been increasing in this high-risk patient population. CRT has beneficial effects on morbidity, mortality, and left ventricular function in patients with non-ischemic cardiomyopathy, yet cancer patients and survivors who develop severe HF and are eligible for CRT often does not receive it.

View complete article: PDF  |  Full-text

This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.

View complete article: PDF  |  Full-text

Palmoplantar Malignant Melanoma (PPMM) is a tumor that arises from the melanocytes of the palmoplantar location. It is usually curable when treated surgically if diagnosed early. Objective: To assess the clinical presentation and treatment outcome of PPMM in Brazzaville Patients and Methods: This is a cross sectional study of thirteen years (January 1998-December 2011). 121 patients with PPMM who received the 3 treatment types were included: Surgery, chemotherapy and combination of surgery and chemotherapy.

View complete article: PDF  |  Full-text

Non Hodgkin’s lymphoma is an extremely chemo sensitive with a five year event free survival of greater than 90% in developed countries and a one year survival rate of 40-50% in developing countries.

View complete article: PDF  |  Full-text